文献速递其他结缔组织病

干扰素-α作为干燥病精准医学工具:队列与实验医学研究

Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study.
PubMed 文献 · Lancet Rheumatol · 2026-07-02

该研究利用英国初级干燥综合征注册队列和UK Biobank数据,结合转基因小鼠模型,发现干燥病患者中IFNα升高可驱动特定免疫内型,且该内型可在诊断前十余年检出,提示IFNα是精准分层候选生物标志物。

要点

  • 干燥病患者中61%(108/177)可检出IFNα升高,且与细胞减少、高丙种球蛋白血症等免疫内型相关。
  • IFNα相关寡蛋白特征可在干燥病诊断前长达14年检出,支持其早期驱动作用。
  • 小鼠慢性IFNα过表达可重现该内型,IFNAR1阻断仅部分逆转,提示持久免疫失调。

核心结论

  • IFNα升高驱动干燥病的一种免疫内型,且可在诊断前十余年检出,支持按精准医学原则进行免疫分层。

研究设计与样本

  • 采用超敏单分子ELISA和基于广泛捕获蛋白质组学的寡蛋白IFN特征评分分析样本。
  • 构建过表达IFNα4的转基因小鼠模型以验证因果方向。

主要发现

  • UKPSSR中177例干燥病患者有108例(61%)IFNα浓度升高。
  • UK Biobank Pharma Proteomics Project中可在诊断前长达14年检出寡蛋白IFN特征。
  • UKPSSR中IFNα升高者具有以细胞减少、高丙种球蛋白血症、多种自身抗体及针对干燥抗原TRIM21/Ro52的自身免疫为特征的独特免疫内型。
  • 系统性慢性IFNα升高小鼠模型重现该内型关键特征,且可被IFNAR1阻断部分逆转。
  • IFNα升高者与正常者在临床上大体相似,但免疫学上截然不同。

关键数值与推荐

  • IFNα升高定义为超敏单分子ELISA检出浓度升高,在UKPSSR中占108/177例(61%)。

临床怎么用

  • 对干燥病患者可考虑检测IFNα浓度以识别免疫内型,辅助精准分层。
  • IFNα升高者临床相似但免疫学不同,提示需用高分辨率生物标志物进行免疫分层而非仅凭临床表型。
  • IFNAR1阻断仅部分逆转慢性IFNα驱动的免疫失调,提示需针对持久免疫 dysregulation 的联合策略。

局限性

  • UKPSSR为观察性队列,样本量有限(177例),IFNα升高比例基于该队列。
  • 小鼠模型为IFNα4过表达,不能完全代表人类干燥病复杂机制。
  • IFNAR1阻断仅部分逆转内型,因果推断需进一步临床干预研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mechanistic heterogeneity is a major obstacle to the development of effective treatment for Sjögren's disease, and there is a pressing need to stratify Sjögren's disease according to precision medicine principles. Aberrant activation of the type 1 interferon (IFN) pathway represents a leading candidate pathway, but a causal role of elevated IFNα in driving Sjögren's disease has yet to be established. We aimed to examine the role of IFNα in driving a Sjögren's disease endotype and relevance to precision medicine principles. METHODS: We used data from the UK Primary Sjögren's Syndrome Registry (UKPSSR), a multicentre observational cohort of participants with Sjögren's disease, and UK Biobank, a large population-based cohort which includes people with and without Sjögren's disease, to study the role of IFNα in Sjögren's disease. Ultrasensitive single molecule ELISA and an oligoprotein IFN signature score derived from broad capture proteomics were used to analyse samples from UKPSSR and data from the UK Biobank Pharma Proteomics Project (a subset of individuals from UK Biobank) to establish the timecourse and immune endotype associated with elevated IFNα. To address causality, we created a new transgenic mouse model of IFNα overexpression to establish whether chronically elevated IFNα drives this immune endotype. People with lived experience of Sjögren's disease were involved in the design of the UKPSSR and shaping of research questions. FINDINGS: Between Aug 1, 2009, and March 31, 2012, we identified 177 people with Sjögren's disease in UKPSSR (mean age 57·5 years [IQR 46·0-65·0], 163 [92%] women, 14 [8%] men, and 162 [92%] White ethnicity). In addition, between March 13, 2006, to Oct 1, 2010, we identified 47 606 people without Sjögren's disease and 257 people with Sjögren's disease in the UK Biobank Pharma Proteomics Project, including 137 individuals sampled before diagnosis. IFNα concentrations were elevated in 108 (61%) of 177 people with Sjögren's disease in the UKPSSR. Oligoprotein IFN signatures were detected up to 14 years before diagnosis of Sjögren's disease in the UK Biobank Pharma Proteomics Project. Individuals in UKPSSR with elevated IFNα had a distinct immunological endotype characterised by cytopenia, hypergammaglobulinaemia, multiple autoantibodies, and autoimmunity against the Sjögren autoantigen TRIM21/Ro52. In a mouse model of systemic chronic IFNα elevation, in which IFNα4 was overexpressed by conventional dendritic cells, the key features of the endotype were recapitulated and could be partly reversed by type 1 interferon receptor (IFNAR1) blockade. INTERPRETATION: We found that the elevation of IFNα drives an immune endotype of Sjögren's disease, and elevated IFNα can be detected over a decade before diagnosis. People with Sjögren's disease with elevated IFNα concentrations were broadly clinically similar to those with normal IFNα concentrations, yet were immunologically distinct. This highlights the mechanistic heterogeneity of Sjögren's disease and the need for immunological stratification along precision medicine principles, using high resolution biomarkers. In addition to demonstrating causal direction, biological modelling in a mouse model showed that chronic IFNα elevation over the lifecourse had the potential to establish persistent immune dysregulation, which responded only partly to IFNAR1 blockade. These findings provide insights into Sjögren's disease and other interferonopathic rheumatological disorders. FUNDING: Precision Medicine Alliance Scotland (Chief Scientist Office, Scottish Government), Wellcome Trust, Medical Research Council UKRI, Deutsche Forschungsgemeinschaft.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Forbes D, Jorgacevic I, Tarn J, et al. Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study. Lancet Rheumatol. 2026. PMID: 42392131. doi:10.1016/S2665-9913(26)00038-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。